CorMedix Inc. (CRMD) announced the pricing of its previously announced underwritten public offering of 6,604,507 shares of its common stock.
The total gross proceeds from the offering to the company are expected to be approximately $85 million.
CorMedix intends to use the net proceeds from the offering for general corporate purposes.
These purposes may include working capital and potential strategic transactions.
Such transactions could involve acquisitions, joint ventures, or collaborations involving companies, products, or assets that complement CorMedix’s business.
The closing of the offering for CorMedix Inc. (CRMD) is anticipated to take place on or about June 30, 2025.